Table 1.

Randomized controlled trials for BRV

Trial	Design (type of trial)	Number of patients treated with BRV	BRV range	Responder rates $50%	Median percent reductions from baseline in seizure frequency/week
French et al30	RCT double-blind vs placebo	154	5–50 mg/d	32.0% for BRV 5 mg/d	29.9% for BRV 5 mg/d
				44.2% for BRV 20 mg/d	42.6% for BRV 20 mg/d
				55.8% for BRV 50 mg/d	53.1% for BRV 50 mg/d
Van Paesschen et al31	RCT double-blind vs placebo	105	50–150 mg/d	35.8% for BRV 50 mg/d	34.9% for BRV 50 mg/d
				30.8% for BRV 150 mg/d	28.3% for BRV 150 mg/d
Ryvlin et al32	RCT double-blind vs placebo	298	20–100 mg/d	27.3% for BRV 20 mg/d	30.0% for BRV 20 mg/d
				27.3% for BRV 50 mg/d	26.8% for BRV 50 mg/d
				36.0% for BRV 100 mg/d	32.5% for BRV 100 mg/d
Biton et al33	RCT double-blind vs placebo	298	5–50 mg/d	21.9% for BRV 5 mg/d	20% for BRV 5 mg/d
				23.2% for BRV 20 mg/d	22.5% for BRV 20 mg/d
				32.7% for BRV 50 mg/d	30.5% for BRV 50 mg/d
Kwan et al35	RCT double-blind vs placebo	323	Flexible doses 20–150 mg/d	30.3% in BRV groups with partial seizures	26.9% in BRV groups with partial seizures
				44.4% in BRV group with	42.6% in BRV group with
				generalized seizures	generalized seizures
Klein et al34	RCT double-blind vs placebo	760	Fixed doses 100–200 mg/d	38.9% for BRV 100 mg/d	22.8% for BRV 100 mg/d
				37.8% for BRV 200 mg/d	23.2% for BRV 200 mg/d

Abbreviations: RCT, randomized clinical trials; BRV, brivaracetam.